SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 146.56 |
Enterprise Value ($M) | 123.13 |
Book Value ($M) | 97.43 |
Book Value / Share | 1.72 |
Price / Book | 1.50 |
NCAV ($M) | 75.07 |
NCAV / Share | 1.33 |
Price / NCAV | 1.95 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.61 |
Return on Assets (ROA) | -0.42 |
Return on Equity (ROE) | -0.54 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 5.55 |
Current Ratio | 5.55 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 115.54 |
Assets | 137.90 |
Liabilities | 40.47 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Vestal Point Capital, LP | 8.90 | ||
13G/A | T. Rowe Price Investment Management, Inc. | 19.00 | 0.70 | |
13G | BlackRock, Inc. | 6.20 | 0.00 | |
13D/A | Versant Venture Capital VI, L.P. | 7.70 | 0.00 | |
13D/A | New Enterprise Associates 16, L.P. | 8.10 | 31.84 | |
13D/A | Ra Capital Management, L.p. | 4.95 | 7.65 | |
13G/A | Bb Biotech Ag | 16.50 | 58.39 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
149,041 | 520,778 | 28.62 | |
135,313 | 643,490 | 21.03 | |
109,647 | 366,923 | 29.88 | |
(click for more detail) |
Similar Companies | |
---|---|
AVXL – Anavex Life Sciences Corp. | BBIO – BridgeBio Pharma, Inc. |
BCRX – BioCryst Pharmaceuticals, Inc. | BEAM – Beam Therapeutics Inc. |
BIIB – Biogen Inc. |
Financial data and stock pages provided by
Fintel.io